Citigroup Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. $SUPN

Citigroup Inc. cut its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 45.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 64,716 shares of the specialty pharmaceutical company’s stock after selling 52,852 shares during the period. Citigroup Inc. owned about 0.12% of Supernus Pharmaceuticals worth $3,093,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of SUPN. Royal Bank of Canada increased its stake in Supernus Pharmaceuticals by 68.1% in the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock worth $2,791,000 after acquiring an additional 22,182 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Supernus Pharmaceuticals by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after purchasing an additional 1,297 shares in the last quarter. Millennium Management LLC raised its stake in Supernus Pharmaceuticals by 370.5% during the 1st quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock valued at $4,695,000 after purchasing an additional 112,886 shares during the period. Finally, Empowered Funds LLC raised its stake in Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock valued at $1,573,000 after purchasing an additional 6,619 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Craig Hallum set a $65.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research cut shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Stifel Nicolaus increased their price objective on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a report on Friday, December 19th. Finally, Wall Street Zen upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Supernus Pharmaceuticals currently has an average rating of “Hold” and an average price target of $62.17.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 20,000 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at approximately $781,153.36. This represents a 56.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bethany Sensenig sold 4,475 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,185 shares of company stock worth $1,268,022 over the last ninety days. Company insiders own 8.80% of the company’s stock.

Supernus Pharmaceuticals Stock Down 2.4%

Shares of NASDAQ:SUPN opened at $54.27 on Friday. The firm has a fifty day simple moving average of $50.94 and a two-hundred day simple moving average of $48.66. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $59.68. The stock has a market capitalization of $3.12 billion, a P/E ratio of -79.81, a PEG ratio of 1.73 and a beta of 0.70.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.